MyMD Pharmaceuticals (MYMD) Competitors $0.15 -0.01 (-6.76%) As of 06/12/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsInsider TradesOptions ChainSEC FilingsTrendsBuy This Stock MYMD vs. MRKR, LPCN, COCP, CING, GELS, NKGN, LEXX, BFRG, PMN, and GOVXShould you be buying MyMD Pharmaceuticals stock or one of its competitors? The main competitors of MyMD Pharmaceuticals include Marker Therapeutics (MRKR), Lipocine (LPCN), Cocrystal Pharma (COCP), Cingulate (CING), Gelteq (GELS), NKGen Biotech (NKGN), Lexaria Bioscience (LEXX), Bullfrog AI (BFRG), ProMIS Neurosciences (PMN), and GeoVax Labs (GOVX). These companies are all part of the "pharmaceutical products" industry. MyMD Pharmaceuticals vs. Its Competitors Marker Therapeutics Lipocine Cocrystal Pharma Cingulate Gelteq NKGen Biotech Lexaria Bioscience Bullfrog AI ProMIS Neurosciences GeoVax Labs Marker Therapeutics (NASDAQ:MRKR) and MyMD Pharmaceuticals (NASDAQ:MYMD) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their community ranking, risk, dividends, earnings, profitability, valuation, media sentiment, institutional ownership and analyst recommendations. Which has preferable valuation & earnings, MRKR or MYMD? MyMD Pharmaceuticals has lower revenue, but higher earnings than Marker Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMarker Therapeutics$6.59M2.75-$8.24M-$1.33-1.20MyMD PharmaceuticalsN/AN/A-$4MN/AN/A Do analysts rate MRKR or MYMD? Marker Therapeutics presently has a consensus price target of $13.17, indicating a potential upside of 722.92%. Given Marker Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Marker Therapeutics is more favorable than MyMD Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Marker Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 3.50MyMD Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media favor MRKR or MYMD? In the previous week, Marker Therapeutics had 2 more articles in the media than MyMD Pharmaceuticals. MarketBeat recorded 2 mentions for Marker Therapeutics and 0 mentions for MyMD Pharmaceuticals. Marker Therapeutics' average media sentiment score of 0.93 beat MyMD Pharmaceuticals' score of 0.00 indicating that Marker Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Marker Therapeutics Positive MyMD Pharmaceuticals Neutral Is MRKR or MYMD more profitable? MyMD Pharmaceuticals has a net margin of 0.00% compared to Marker Therapeutics' net margin of -179.74%. Marker Therapeutics' return on equity of -89.63% beat MyMD Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Marker Therapeutics-179.74% -89.63% -71.62% MyMD Pharmaceuticals N/A -179.05%-108.14% Do institutionals & insiders have more ownership in MRKR or MYMD? 22.4% of Marker Therapeutics shares are owned by institutional investors. Comparatively, 9.6% of MyMD Pharmaceuticals shares are owned by institutional investors. 14.5% of Marker Therapeutics shares are owned by insiders. Comparatively, 2.1% of MyMD Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has more volatility & risk, MRKR or MYMD? Marker Therapeutics has a beta of 1.44, meaning that its stock price is 44% more volatile than the S&P 500. Comparatively, MyMD Pharmaceuticals has a beta of 2.15, meaning that its stock price is 115% more volatile than the S&P 500. Does the MarketBeat Community believe in MRKR or MYMD? Marker Therapeutics received 75 more outperform votes than MyMD Pharmaceuticals when rated by MarketBeat users. CompanyUnderperformOutperformMarker TherapeuticsOutperform Votes7564.66% Underperform Votes4135.34% MyMD PharmaceuticalsN/AN/A SummaryMarker Therapeutics beats MyMD Pharmaceuticals on 12 of the 15 factors compared between the two stocks. Get MyMD Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for MYMD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MYMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MYMD vs. The Competition Export to ExcelMetricMyMD PharmaceuticalsDiagnostic substances IndustryMedical SectorNASDAQ ExchangeMarket Cap$363K$2.68B$5.58B$8.50BDividend YieldN/A0.70%5.28%4.17%P/E RatioN/A7.7427.1919.64Price / SalesN/A35.24408.78152.17Price / CashN/A15.7538.3234.64Price / Book0.025.416.974.60Net Income-$4M-$65.73M$3.23B$248.06M7 Day Performance-4.01%-3.80%-0.88%-1.02%1 Month Performance-21.84%-0.50%7.81%3.51%1 Year Performance-92.97%-21.63%31.53%12.68% MyMD Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MYMDMyMD PharmaceuticalsN/A$0.15-6.8%N/A-91.4%$363KN/A0.006Gap DownHigh Trading VolumeMRKRMarker Therapeutics4.2853 of 5 stars$1.52+7.8%$13.17+766.2%-57.8%$17.20M$6.59M-1.1460Positive NewsLPCNLipocine2.3266 of 5 stars$3.20-2.4%$9.00+181.3%-60.3%$17.12M$3.67M-4.2110News CoverageAnalyst ForecastAnalyst RevisionGap DownCOCPCocrystal Pharma2.6498 of 5 stars$1.68+1.8%$7.00+316.7%-45.0%$17.09MN/A-0.9110Short Interest ↑Gap UpCINGCingulate1.9415 of 5 stars$3.98flat$26.00+553.3%+535.7%$16.90MN/A-0.4720Short Interest ↑Gap DownGELSGelteqN/A$1.79+19.3%N/AN/A$16.89MN/A0.00N/ANKGNNKGen Biotech0.8178 of 5 stars$0.38+4.2%N/A-73.8%$16.86M$80K-0.07N/AGap UpLEXXLexaria Bioscience2.5389 of 5 stars$0.92-5.7%$7.00+659.9%-68.5%$16.18M$525.92K-1.847News CoverageBFRGBullfrog AI1.6602 of 5 stars$1.71flatN/A-33.2%$16.10M$60K-2.014News CoveragePMNProMIS Neurosciences2.3518 of 5 stars$0.49-2.0%$4.50+818.4%-69.0%$16.02MN/A-4.905Positive NewsGOVXGeoVax Labs3.3946 of 5 stars$1.05+1.0%$11.10+957.1%-23.1%$15.95M$5.59M-0.2910News Coverage Related Companies and Tools Related Companies MRKR Alternatives LPCN Alternatives COCP Alternatives CING Alternatives GELS Alternatives NKGN Alternatives LEXX Alternatives BFRG Alternatives PMN Alternatives GOVX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MYMD) was last updated on 6/13/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MyMD Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MyMD Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy MYMD Stock Free MYMD Stock Alerts